• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

C 反应蛋白与肠型贝赫切特病患者的术后结局相关。

C-reactive protein is associated with postoperative outcomes in patients with intestinal Behçet's disease.

机构信息

Gastroenterology and Department of Internal Medicine, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 03722, Republic of Korea.

Division of Colon and Rectal Surgery, Department of Surgery, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 03722, Republic of Korea.

出版信息

BMC Gastroenterol. 2021 Oct 7;21(1):362. doi: 10.1186/s12876-021-01922-2.

DOI:10.1186/s12876-021-01922-2
PMID:34620099
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8496041/
Abstract

BACKGROUND

Patients with intestinal Behçet's disease (BD) frequently undergo intestinal resections, which significantly affects postoperative morbidity and mortality. The aim of this study was to identify the association between C-reactive protein (CRP) levels and postoperative outcomes in patients with intestinal BD who underwent surgical bowel resection.

METHODS

Patients who were diagnosed with intestinal BD and underwent intestinal surgery due to BD at Severance Hospital between November 2005 and April 2018 were retrospectively investigated. Clinical relapse was defined as a disease activity index of BD (DAIBD) > 40, existence of newly added medications, re-hospitalization, or re-operation related to intestinal BD. The relationship between CRP level and postoperative outcomes was analyzed, and a receiver operating characteristic (ROC) curve was drawn to specify a cut-off value.

RESULTS

Ninety patients with intestinal BD were included. Among them, 44 were male (48.9%), and the median age at diagnosis was 38 years (range, 11-69 years). The median total disease follow-up duration was 130 months (range, 3-460 months). Forty patients (44.4%) underwent laparoscopic surgery. A higher CRP level immediately after surgery was significantly associated with postoperative complications (OR 1.01, 95% CI 1.004-1.018, p < 0.01), re-operation (hazard ratio [HR] 1.01, 95% CI 1.005-1.020, p < 0.01), and re-admission (HR 1.01, 95% CI 1.006-1.017 p < 0.01). The ROC curve showed that CRP predicts the risk of postoperative complications (p < 0.01) at a cut-off value of 41.9% with a sensitivity of 60.0% and specificity of 67.7%.

CONCLUSIONS

Postoperative CRP levels in patients with intestinal BD undergoing surgical resection were associated with postoperative outcomes.

摘要

背景

患有肠道贝赫切特病(BD)的患者经常需要进行肠道切除术,这会显著影响术后发病率和死亡率。本研究旨在确定 C 反应蛋白(CRP)水平与接受肠道 BD 手术的患者术后结局之间的关系。

方法

回顾性调查了 2005 年 11 月至 2018 年 4 月在 Severance 医院因 BD 接受肠道手术的肠道 BD 患者。临床复发定义为 BD 疾病活动指数(DAIBD)>40、存在新添加的药物、因 BD 再次住院或再次手术。分析了 CRP 水平与术后结局的关系,并绘制了受试者工作特征(ROC)曲线以确定临界值。

结果

纳入了 90 例肠道 BD 患者,其中 44 例为男性(48.9%),诊断时的中位年龄为 38 岁(范围,11-69 岁)。中位总疾病随访时间为 130 个月(范围,3-460 个月)。40 例(44.4%)接受了腹腔镜手术。术后即刻 CRP 水平较高与术后并发症显著相关(OR 1.01,95%CI 1.004-1.018,p<0.01)、再次手术(风险比 [HR] 1.01,95%CI 1.005-1.020,p<0.01)和再次入院(HR 1.01,95%CI 1.006-1.017,p<0.01)。ROC 曲线显示 CRP 在截值为 41.9%时预测术后并发症的风险(p<0.01),敏感性为 60.0%,特异性为 67.7%。

结论

接受肠道切除术的肠道 BD 患者术后 CRP 水平与术后结局相关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5bc2/8496041/3557741466e9/12876_2021_1922_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5bc2/8496041/7eea2e5e5619/12876_2021_1922_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5bc2/8496041/3557741466e9/12876_2021_1922_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5bc2/8496041/7eea2e5e5619/12876_2021_1922_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5bc2/8496041/3557741466e9/12876_2021_1922_Fig2_HTML.jpg

相似文献

1
C-reactive protein is associated with postoperative outcomes in patients with intestinal Behçet's disease.C 反应蛋白与肠型贝赫切特病患者的术后结局相关。
BMC Gastroenterol. 2021 Oct 7;21(1):362. doi: 10.1186/s12876-021-01922-2.
2
Development of a Novel Endoscopic Scoring System to Predict Relapse after Surgery in Intestinal Behçet's Disease.开发一种新的内镜评分系统预测肠白塞病手术后复发。
Gut Liver. 2018 Nov 15;12(6):674-681. doi: 10.5009/gnl17547.
3
Short- and long-term outcomes of laparoscopic surgery for intestinal Behcet's disease: a comparative study with open surgery.腹腔镜手术治疗肠道白塞病的短期和长期结果:与开放手术的比较研究
Surg Endosc. 2016 Jan;30(1):99-105. doi: 10.1007/s00464-015-4166-1. Epub 2015 Mar 24.
4
Risk Factors and Outcomes of Emergency Room Visits in Intestinal Behçet's Disease.肠白塞病患者急诊就诊的风险因素和结局。
Digestion. 2017 Nov;96(4):231-238. doi: 10.1159/000484084. Epub 2017 Nov 2.
5
Long-Term Outcomes and Predictors of Sustained Response in Patients with Intestinal Behcet's Disease Treated with Infliximab.英夫利昔单抗治疗的肠道白塞病患者持续缓解的长期结局及预测因素
Dig Dis Sci. 2017 Feb;62(2):441-447. doi: 10.1007/s10620-016-4395-8. Epub 2017 Jan 2.
6
Expression of a soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) correlates with clinical disease activity in intestinal Behcet's disease.可溶性髓系细胞触发受体-1(sTREM-1)的表达与肠型贝赫切特病的临床疾病活动相关。
Inflamm Bowel Dis. 2011 Oct;17(10):2130-7. doi: 10.1002/ibd.21600. Epub 2011 Jan 6.
7
Prediction of free bowel perforation in patients with intestinal Behçet's disease using clinical and colonoscopic findings.基于临床和结肠镜检查结果预测肠型贝赫切特病患者的肠穿孔风险。
Dig Dis Sci. 2010 Oct;55(10):2904-11. doi: 10.1007/s10620-009-1095-7. Epub 2010 Jan 22.
8
Influence of age at diagnosis and sex on clinical course and long-term prognosis of intestinal Behcet's disease.发病年龄和性别对肠型贝赫切特病临床病程和长期预后的影响。
Inflamm Bowel Dis. 2012 Jun;18(6):1064-71. doi: 10.1002/ibd.21833. Epub 2011 Jul 26.
9
Incidence and risk factors for anemia among newly-diagnosed intestinal Behcet's disease patients.初诊肠型贝赫切特病患者贫血的发生率及相关危险因素。
J Natl Med Assoc. 2019 Aug;111(4):407-412. doi: 10.1016/j.jnma.2019.01.010. Epub 2019 Feb 23.
10
Postoperative Effects of Thiopurines in Patients with Intestinal Behçet's Disease.硫唑嘌呤对肠道白塞病患者的术后影响
Dig Dis Sci. 2015 Dec;60(12):3721-7. doi: 10.1007/s10620-015-3799-1. Epub 2015 Jul 22.

引用本文的文献

1
Postoperative complications in patients with Behçet's disease.贝切特病患者的术后并发症。
Clin Rheumatol. 2024 Dec;43(12):3829-3838. doi: 10.1007/s10067-024-07212-y. Epub 2024 Oct 29.
2
Intestinal Behçet's disease: A review of clinical diagnosis and treatment.肠道白塞病:临床诊断与治疗综述
World J Gastrointest Surg. 2024 Jun 27;16(6):1493-1500. doi: 10.4240/wjgs.v16.i6.1493.
3
Effectiveness and safety of adalimumab in patients with intestinal Behçet's disease: a real-world prospective observational study in South Korea.

本文引用的文献

1
Deep-learning system for real-time differentiation between Crohn's disease, intestinal Behçet's disease, and intestinal tuberculosis.基于深度学习的克罗恩病、肠型贝赫切特病和肠结核实时鉴别系统。
J Gastroenterol Hepatol. 2021 Aug;36(8):2141-2148. doi: 10.1111/jgh.15433. Epub 2021 Feb 20.
2
Mucosal healing in intestinal Behçet's disease: A systematic review and meta-analysis.肠白塞病的黏膜愈合:系统评价和荟萃分析。
J Dig Dis. 2021 Feb;22(2):83-90. doi: 10.1111/1751-2980.12965. Epub 2021 Jan 22.
3
Long-term safety and effectiveness of adalimumab in 462 patients with intestinal Behçet’s disease: results from a large real-world observational study.
阿达木单抗治疗肠型贝赫切特病患者的有效性和安全性:韩国真实世界前瞻性观察性研究。
BMC Gastroenterol. 2023 Dec 19;23(1):449. doi: 10.1186/s12876-023-03090-x.
4
C-Reactive Protein: Pathophysiology, Diagnosis, False Test Results and a Novel Diagnostic Algorithm for Clinicians.C反应蛋白:病理生理学、诊断、检测结果假阳性及面向临床医生的新型诊断算法
Diseases. 2023 Sep 28;11(4):132. doi: 10.3390/diseases11040132.
462例肠道白塞病患者使用阿达木单抗的长期安全性和有效性:一项大型真实世界观察性研究的结果
Intest Res. 2021 Jul;19(3):301-312. doi: 10.5217/ir.2020.00013. Epub 2020 Aug 20.
4
Evidence-based diagnosis and clinical practice guidelines for intestinal Behçet's disease 2020 edited by Intractable Diseases, the Health and Labour Sciences Research Grants.《2020 年肠型贝赫切特病循证诊断与临床实践指南》,特发性疾病,健康与劳动科学研究补助金编辑。
J Gastroenterol. 2020 Jul;55(7):679-700. doi: 10.1007/s00535-020-01690-y. Epub 2020 May 7.
5
Serum C-reactive protein and albumin are useful biomarkers for tight control management of Crohn's disease in Japan.血清 C 反应蛋白和白蛋白是日本克罗恩病紧密控制管理的有用生物标志物。
Sci Rep. 2020 Jan 16;10(1):511. doi: 10.1038/s41598-020-57508-7.
6
High risk of septic complications following surgery for Crohn's disease in patients with preoperative anaemia, hypoalbuminemia and high CRP.术前贫血、低蛋白血症和 CRP 升高的克罗恩病患者术后发生脓毒症并发症的风险高。
Int J Colorectal Dis. 2019 Dec;34(12):2185-2188. doi: 10.1007/s00384-019-03427-7. Epub 2019 Nov 8.
7
KIR3DL1/S1 Allotypes Contribute Differentially to the Development of Behçet Disease.KIR3DL1/S1 同种异型对贝赫切特病的发展有不同的影响。
J Immunol. 2019 Sep 15;203(6):1629-1635. doi: 10.4049/jimmunol.1801178. Epub 2019 Aug 12.
8
Comparative study of corticosteroid monotherapy, and TNF inhibitors with or without corticosteroid in patients with refractory entero-Behcet's disease.难治性肠白塞病患者中单用皮质类固醇激素与 TNF 抑制剂联合或不联合皮质类固醇激素治疗的对比研究。
Arthritis Res Ther. 2019 Jun 22;21(1):151. doi: 10.1186/s13075-019-1933-8.
9
Remission induction, maintenance, and endoscopic outcome with oral 5-aminosalicylic acid in intestinal Behçet's disease.肠白塞病患者口服 5-氨基水杨酸诱导缓解、维持缓解及内镜下缓解的效果。
J Gastroenterol Hepatol. 2019 Nov;34(11):1929-1939. doi: 10.1111/jgh.14690. Epub 2019 Jun 20.
10
Real-world efficacy of adalimumab and infliximab for refractory intestinal Behçet's disease.阿达木单抗和英夫利昔单抗治疗难治性肠白塞病的真实世界疗效。
Dig Liver Dis. 2019 Jul;51(7):967-971. doi: 10.1016/j.dld.2018.10.024. Epub 2019 Feb 19.